FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   McIntyre Gail Frances 2. Date of Event Requiring Statement (Month/Day/Year) 02/12/2019 3. Issuer Name and Ticker or Trading Symbol Aravive, Inc. [ARAV] (Last) (First) (Middle) C/O ARAVIVE, INC., LYONDELLBASSELL TOWER, 1221 MCKINNEY ST., STE 3200 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) HOUSTON, TX 77010 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	  (1)(2)	06/14/2027	Common Stock	29,641	$ 0.66	D	Â
Stock Option	  (1)(3)	12/13/2027	Common Stock	14,820	$ 0.9	D	Â
Stock Option	  (1)(4)	03/19/2028	Common Stock	14,820	$ 0.9	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
McIntyre Gail Frances C/O ARAVIVE, INC., LYONDELLBASSELL TOWER 1221 MCKINNEY ST., STE 3200 HOUSTON, TX 77010	Â	Â	  Chief Scientific Officer	Â

Signatures

/s/ Gail F. McIntyre		02/25/2019
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive Biologics") were converted into shares of Aravive, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer (then under the name Versartis, Inc.), Velo Merger Sub, Inc. and Aravive Biologics (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement for the merger (the "Merger"), each share of Aravive Biologics common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the Merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split.
(2)	On June 15, 2017, the reporting person was granted an option to purchase 78,000 shares of common stock of Aravive Biologics at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 29,641 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger.
(3)	December 14, 2017, the reporting person was granted an option to purchase 39,000 shares of common stock of Aravive Biologics at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 14,820 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger.
(4)	On March 20, 2018, the reporting person was granted an option to purchase 39,000 shares of common stock of Aravive Biologics at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 14,820 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.